Objectives: To evaluate the efficacy and safety of the antidepressant valdoxan in irritable bowel syndrome (IBS) with comorbid mild and moderate depression.
Methods: Twenty-eight patients with IBS and depression without psychotic symptoms were studied using clinical examination and psychometric scales.
Results: A significant reduction in psychopathological symptoms, along with the improvement of health status, was recorded for most patients treated with valdoxan (25-50 mg/night) in the end of the 1st week.
Conclusion: Valdoxan has a good tolerability and safety profile, does not exert any negative effect on the IBS course and provides a high level of compliance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
AGA Institute Quality Indicator Development for Irritable Bowel Syndrome.
Gastroenterology
January 2025
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana; Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.
(CECT7484 and CECT7485) and (CECT7483) enhance actin cytoskeleton and CYP1A1 expression restoring epithelial permeability alterations induced by irritable bowel syndrome mediators.
Gut Microbes
December 2025
Gastroenterology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Irritable bowel syndrome (IBS) is a multifactorial condition with heterogeneous pathophysiology, including intestinal permeability alterations. The aim of the present study was to assess the ability of a probiotic blend (PB) consisting of two strains (CECT7484 and CECT7485) and one strain of (CECT7483) to recover the permeability increase induced by mediators from IBS mucosal biopsies and to highlight the underlying molecular mechanisms. Twenty-one IBS patients diagnosed according to ROME IV criteria (11 IBS-D and 10 IBS-M) and 7 healthy controls were enrolled.
View Article and Find Full Text PDFClinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.
Aliment Pharmacol Ther
January 2025
Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, Massachusetts, USA.
Introduction: Despite the emergence of drugs to treat irritable bowel syndrome (IBS), improving abdominal pain can still be challenging. αδ ligands, such as gabapentin and pregabalin, are sometimes used off-label to tackle this problem. However, evidence for efficacy is limited, and no large-scale studies have been published.
View Article and Find Full Text PDFAnxiety disorders presenting as gastrointestinal symptoms in children - a scoping review.
Clin Exp Pediatr
January 2025
Morriston Hospital, Swansea, United Kingdom.
Functional gastrointestinal disorders (FGID) and their association with anxiety disorders in children significantly impact a child's functioning and treatment response. This study aimed to scope the evidence of anxiety disorders manifesting as FGID in children up to 16 years old. A comprehensive search strategy was conducted on Embase (1974-2024), Medline (via EBSCOHost 1946-2024), and APA PsycINFO (via EBSCOHost 1967-2024).
View Article and Find Full Text PDF[Functional disorders in chronic inflammatory bowel disease: the gut-brain axis].
Inn Med (Heidelb)
January 2025
Medizinische Klinik 2, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 83477, München, Deutschland.
Background: In patients with inflammatory bowel diseases (IBD), functional complaints frequently persist after the clearing of inflammation and are clinically difficult to distinguish from symptoms of inflammation. In recent years, the influence of bidirectional communication between the gut and brain on gut physiology, emotions, and behavior has been demonstrated.
Research Questions: What mechanisms underlie the development of functional gastrointestinal complaints in patients with irritable bowel syndrome (IBS) and IBD? What therapeutic approaches arise from this?
Materials And Methods: Narrative review.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!